235 related articles for article (PubMed ID: 17905680)
1. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.
Thomsen HS; Marckmann P; Logager VB
Cancer Imaging; 2007 Sep; 7(1):130-7. PubMed ID: 17905680
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Gd-CA: differences in prevalence of NSF.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
[TBL] [Abstract][Full Text] [Related]
3. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
[TBL] [Abstract][Full Text] [Related]
4. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
Heinrich M; Uder M
Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
[TBL] [Abstract][Full Text] [Related]
5. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
6. Update on nephrogenic systemic fibrosis.
Thomsen HS; Marckmann P; Logager VB
Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
[TBL] [Abstract][Full Text] [Related]
7. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
Andréjak M; Thuillier D; Lok C; Gras-Champel V
Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
Perazella MA
Curr Drug Saf; 2008 Jan; 3(1):67-75. PubMed ID: 18690983
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI.
Issa N; Poggio ED; Fatica RA; Patel R; Ruggieri PM; Heyka RJ
Cleve Clin J Med; 2008 Feb; 75(2):95-7, 103-4, 106 passim. PubMed ID: 18290353
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Broome DR
Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
[TBL] [Abstract][Full Text] [Related]
11. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent].
van der Meij N; Keur I; van Lienden KP; Scheepstra CG; Bos JD
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2898-903. PubMed ID: 18257437
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: more questions and some answers.
Morcos SK; Thomsen HS
Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
Peak AS; Sheller A
Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
[TBL] [Abstract][Full Text] [Related]
14. [Nephrogenic systemic fibrosis].
Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
[TBL] [Abstract][Full Text] [Related]
15. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
Reilly RF
Clin J Am Soc Nephrol; 2008 May; 3(3):747-51. PubMed ID: 18287249
[TBL] [Abstract][Full Text] [Related]
16. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
19. Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.
Bruno F; DeAguero J; Do C; Lee DY; Tan C; Escobar GP; Wagner B
Am J Physiol Renal Physiol; 2021 Apr; 320(4):F617-F627. PubMed ID: 33615889
[TBL] [Abstract][Full Text] [Related]
20. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
